Dr. Andrea Podczeck-Schweighhofer, president of the Austrian Society of Cardiology, the representative voice of the Austrian cardiology ecosystem, provides an overview into the challenges associated with research in Austria and how innovation and drug diversity is being stifled under the current reimbursement system. She also gives insights into Austria´s interaction with the European Society of Cardiology and the potential of Austria becoming more prominent in the cardiological ecosystem.
As the President, could you introduce the Austrian Society of Cardiology (ASC) to our international readers?
"Today in Austria 42.8 percent of mortalities are attributed to cardiovascular disease, the greatest killer in our society, well ahead of second placed cancer at 24.5 percent."
